Abstract：
BACKGROUND: Neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) are accepted standards of care for the management of adenocarcinoma of the esophagus and gastroesophageal junction.
CONCLUSIONS: The MRC-OEO2 study established the role of 2 cycles of neoadjuvant cisplatin/fluoropyrimidine. More recently, the FLOT-AIO4 study demonstrated the superiority of perioperative FLOT chemotherapy (5FU, oxaliplatin, and docetaxel) compared to ECX (epirubicin, cisplatin, and capecitabine) regime. The results from the pivotal CROSS study established neoadjuvant CRT as a new standard of care in OG cancer. The survival benefits observed in FLOT and CROSS studies are similar [FLOT - hazard ratio 0.75 (0.62-0.92); CROSS - 0.741 (0.55-0.98)].
CONCLUSIONS: Both nCT and nCRT have been shown to be associated with survival benefit compared to surgery alone. We have performed a comprehensive review of the available evidence to define the optimum treatment algorithm and identify specific patient sub-groups who may be appropriate for the use of one or more of these neoadjuvant options.
CONCLUSIONS: The MRC-OEO2 study established the role of 2 cycles of neoadjuvant cisplatin/fluoropyrimidine. More recently, the FLOT-AIO4 study demonstrated the superiority of perioperative FLOT chemotherapy (5FU, oxaliplatin, and docetaxel) compared to ECX (epirubicin, cisplatin, and capecitabine) regime. The results from the pivotal CROSS study established neoadjuvant CRT as a new standard of care in OG cancer. The survival benefits observed in FLOT and CROSS studies are similar [FLOT - hazard ratio 0.75 (0.62-0.92); CROSS - 0.741 (0.55-0.98)].
CONCLUSIONS: Both nCT and nCRT have been shown to be associated with survival benefit compared to surgery alone. We have performed a comprehensive review of the available evidence to define the optimum treatment algorithm and identify specific patient sub-groups who may be appropriate for the use of one or more of these neoadjuvant options.
摘要：
背景：新辅助化疗（nCT）或放化疗（CRT）是治疗食管和胃食管交界处（GOJ）腺癌（AC）的公认护理标准。
结论：MRC-OEO2研究确定了新辅助顺铂/氟嘧啶（FP）2个周期的作用。最近,FLOT-AIO4研究证明了围手术期FLOT化疗的优越性（5FU，奥沙利铂和多西他赛）与ECX（表柔比星，顺铂和卡培他滨)方案。关键CROSS研究的结果确立了新辅助CRT作为OG癌症的新护理标准。在FLOT和CROSS研究中观察到的生存益处相似[FLOT-HR0.75(0.62-0.92);CROSS-0.741(0.55-0.98)]。
结论：与单纯手术相比，nCT和nCRT均与生存获益相关。我们对现有证据进行了全面审查，以定义最佳治疗算法，并确定可能适合使用一种或多种新辅助治疗方案的特定患者亚组。
结论：MRC-OEO2研究确定了新辅助顺铂/氟嘧啶（FP）2个周期的作用。最近,FLOT-AIO4研究证明了围手术期FLOT化疗的优越性（5FU，奥沙利铂和多西他赛）与ECX（表柔比星，顺铂和卡培他滨)方案。关键CROSS研究的结果确立了新辅助CRT作为OG癌症的新护理标准。在FLOT和CROSS研究中观察到的生存益处相似[FLOT-HR0.75(0.62-0.92);CROSS-0.741(0.55-0.98)]。
结论：与单纯手术相比，nCT和nCRT均与生存获益相关。我们对现有证据进行了全面审查，以定义最佳治疗算法，并确定可能适合使用一种或多种新辅助治疗方案的特定患者亚组。
